Chemo with targeted therapy for new Ph+ ALL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of chemotherapy and targeted immunotherapy for people with a specific type of leukemia (Ph+ ALL) that has not been treated before. The goal is to see if this approach can help control the disease better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are newly diagnosed with a type of leukemia called Ph+ ALL, confirmed by a special test.
- Your age is 14 or older.
- Your general health is good enough to do daily activities (ECOG score 0, 1, or 2).
- Your liver, kidneys, heart, and pancreas are working well, based on recent blood tests.
- You have not had a heart attack in the last year or any uncontrolled heart problems.
- You agree to use effective birth control if you are able to have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs given before a stem cell transplant for people with a specific type of acute lymphoblastic leukemia (Ph+ ALL) that did not fully respond to initial treatment. The goal is to make the leukemia undetectable before transplant, which may improve outcomes.
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
This trial combines a targeted antibody therapy with a low dose of chemotherapy to treat adults newly diagnosed with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The goal is to see if this combo can help shrink or eliminate the leukemia with fewer side effects than standard treatment.
This trial tests a combination of targeted drugs (ABL/JAK inhibitors) with chemotherapy and venetoclax for people with a type of leukemia called Ph-like ALL. It aims to see if this treatment is safe and effective.
This trial combines a kid-inspired chemotherapy backbone with a targeted pill (venetoclax) and immunotherapy (special antibodies) to treat adults with Ph-negative acute lymphoblastic leukemia (ALL). The goal is to use a more effective, less toxic approach developed for children.
This trial tests combining a targeted drug (TKI) with chemotherapy and then CAR-T cells for adults who are newly diagnosed with Philadelphia chromosome-positive ALL. The goal is to see if this combination is safe and effective.
Hear when a new Ph+ ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.